Asset Details
Do you wish to reserve the book?
Identifying Dihydropyrimidine Dehydrogenase as a Novel Regulator of Hepatic Steatosis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Identifying Dihydropyrimidine Dehydrogenase as a Novel Regulator of Hepatic Steatosis
Do you wish to request the book?
Identifying Dihydropyrimidine Dehydrogenase as a Novel Regulator of Hepatic Steatosis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Paper
Identifying Dihydropyrimidine Dehydrogenase as a Novel Regulator of Hepatic Steatosis
2021
Overview
Abstract Pyrimidine catabolism is implicated in hepatic steatosis. Dihydropyrimidine Dehydrogenase (DPYD) is an enzyme responsible for uracil and thymine catabolism, and DPYD human genetic variability affects clinically observed toxicity following 5-Fluorouracil (5-FU) administration. In an in vitro model of diet-induced steatosis, the pharmacologic inhibition of DPYD resulted in protection from lipid accumulation. Additionally, a gain-of-function mutation of DPYD, created through clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) engineering, led to an increased lipid burden, which was associated with altered mitochondrial functionality in a hepatocarcionma cell line. The studies presented herein describe a novel role for DPYD in hepatocyte metabolic regulation as a modulator of hepatic steatosis. Competing Interest Statement The authors have declared no competing interest. Footnotes * Shorten methods and grammatical edits * Abbreviations 5-FU (5-Fluorouracil) CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) DPYD (dihydropyrimidine dehydrogenase) FASN (fatty acid synthase) FXR (farsenoid X receptor) G0S2 (G0/G1 Switch Gene 2) HMGCS1 (3-Hydroxy-3-Methylglutaryl-CoA Synthase 1) HSD17B13 (hepatic lipid droplet protein hydroxysteroid 17-beta dehydrogenase 13) MID1IP1 (MID1 interacting protein 1) NAFLD (nonalcoholic fatty liver disease) NASH (non-alcoholic steatohepatitis) PHH (primary human hepatocyte) PNPLA3 (Patatin Like Phospholipase Domain Containing 3) TXNIP (thioredoxin interacting protein 1) UPP1 (uridine phosphorylase-1)
